Home Self Admin denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for home self admin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Home Self-Administration as Not FDA-Approved — and How to Appeal

A "not FDA-approved" denial for home self-administration means Humana's reviewer determined that the specific use being requested — the drug, the delivery route, the device, or the indication — does not have FDA approval or clearance. This denial can arise from a genuine off-label use, but it also commonly results from a reviewer applying an outdated coverage policy that has not caught up with a recent FDA approval, or from confusing approval of the intravenous formulation with approval of a home self-administration formulation.

### Why This Denial Is Appealable

If the drug and the home self-administration route are in fact FDA-approved for the patient's indication, the denial rests on a factual error and should be overturned on internal appeal with clear documentation of the approval. If the use is genuinely off-label, the appeal becomes more complex but is still viable: many state and federal standards require plans to cover off-label uses that are supported by established compendia (e.g., recognized medical compendia used in oncology and other specialties) or by substantial clinical evidence, even absent a specific FDA indication.

### Federal Appeal Rights

• Internal appeal: File within the timeframe on the denial notice. Include FDA labeling documentation as the primary exhibit. Humana must respond within 30 days for standard pre-service appeals.
• External review (ACA §2719 / ERISA §503): After a final internal denial you have the right to independent external review, generally within four months. External reviewers are required to apply generally accepted standards of medical practice, which may include recognized off-label uses.
• Expedited review: Request this if the standard timeline poses a serious health risk; decision typically required within 72 hours.

### Documentation to Gather

1. FDA approval documentation: A copy of the current FDA-approved prescribing label confirming approval of the drug, the delivery route, and the indication. If the approval is recent, include the FDA approval letter or the updated label. 2. Clarification of the specific use: A written statement from the prescriber precisely describing what is being requested — drug name, formulation, route of administration, and indication — so there is no ambiguity about what the FDA approval covers. 3. Prescriber medical-necessity and approval letter: A letter attesting that the requested use is within the FDA-approved indication and is appropriate for this patient. 4. Compendia support (if off-label): If the use is off-label, identify the relevant recognized medical compendium or published clinical guideline organization that supports the use, without citing specific trial statistics. 5. Humana's policy: Obtain Humana's current coverage policy for the drug and identify the specific FDA-approval criterion being applied, so the appeal can address it directly.

### Criteria-Mapping Structure

List the specific FDA-approval criteria from Humana's policy. For each one, provide the corresponding FDA label page, approval document, or compendium reference that satisfies the criterion. If the denial resulted from a reviewer error, state that clearly and attach the corrective documentation prominently at the front of the appeal packet.

Always verify current FDA approval status directly from the FDA label before filing.